N/A N=33 Randomized Prevention

Exercise and the Receptor for Advanced Glycation End Products (RAGE)

Diabetes Mellitus, Type 2

Bottom Line

View on ClinicalTrials.gov: NCT03534687 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2024

Primary outcome: Primary: Quantify the Percentage Change in Basal Circulating sRAGE After 12-weeks of Supervised Aerobic Exercise Training. — 24.5; 0.5 Percent Change in sRAGE

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Aerobic Exercise (Behavioral)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: University of Michigan
Primary completion: May 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Quantify the Percentage Change in Basal Circulating sRAGE After 12-weeks of Supervised Aerobic Exercise Training.	24.5; 0.5	—
SECONDARY Quantify the Percentage Change in Basal Muscle RAGE Expression After 12-weeks of Supervised Aerobic Exercise Training.	-14.5; 4.45	—
SECONDARY Quantify the Percentage Change in Aerobic Capacity (VO2max) After 12-weeks of Supervised Aerobic Exercise Training.	6.9; 0.6	—
SECONDARY Quantify the Percentage Change in Insulin Sensitivity After 12-weeks of Supervised Aerobic Exercise Training.	79; 9	—

Summary

This study examines the effects of 12-weeks of aerobic exercise training on the mechanisms driving RAGE-mediated inflammation in type 2 diabetic humans.

Eligibility Criteria

Inclusion Criteria

Age 40-75 y
Type 2 diabetes
Overweight or obese (BMI 26-44 kg/m2)
Fluency in English (written and verbal)

Exclusion Criteria

Age 75 y
BMI 44 kg/m2
Existing cardiovascular, cerebrovascular, renal, or hematological disease, or cancer
Current use of tobacco
Pregnant or lactating
Medications that may interfere with study outcomes

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03534687). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.